†rsrapport Nycomed - Takeda Pharmaceuticals International GmbH

THIS IS NYCOMED HOLDING A/SNycomed Holding A/S was a dormant company until May 14th, 1999. At thatdate, investors represented by Nordic Capital III Limited subscribed for 68.9%(DKK 571 million including premium) and Nycomed Amersham Benelux BV subscribedfor 31.1% (DKK 257 million including premium) of the share capital ofNycomed Holding A/S.Nycomed Holding A/S directly and indirectly acquired all companies and assetsof the Nycomed Pharma division owned by Nycomed Amersham plc. The purchaseswere financed with external debt of DKK 2,712 million, a loan fromNycomed Amersham plc of DKK 509 million and the subscribed equity of DKK828 million. The total financing exceeded the acquisition of shares by DKK 723million, which was used to replace external debt in the acquired companies.The new Nycomed group (hereafter ”Nycomed”) sources, manufactures and marketspharmaceuticals and consumer health products. Nycomed's revenues in2000 amounted to DKK 3,429 million. Earnings before interest, taxes, depreciationand amortization were DKK 680 million, an increase of 23.2 % over the fullyear 1999. Operating profit was DKK 293 million. The total number of employeeswas 2,372 at 31 st December 2000.The calcium portfolio is Nycomed’s largest product. Xefo ® (lornoxicam),TachoComb ® , Pantoprazole, Gutron ® and Kestine ® are other international key products.Nycomed has sales organisations in the Nordic countries, Benelux, Austria,Germany, Switzerland, Greece, CIS, the Baltic States and China. Sales in otherimportant markets are made through partners.–3–